NCT06871410 2026-01-26Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRoswell Park Cancer InstitutePhase 1 Recruiting26 enrolled